Answers are grounded in this paper and cite their sources.
Pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains a major clinical challenge driven by molecular heterogeneity and therapeutic resistance. While the SWI/SNF chromatin-remodeling complex is a recognized dependency in myeloid and T-cell leukemias, its role in B-ALL remains poorly defined. Here, we identify a conserved requirement for the SWI/SNF ATPases SMARCA4 and SMARCA2 across diverse B-ALL genetic subtypes. SMARCA4 expression correlates with inferior overall survival in the pediatric B-ALL TARGET cohort. Using a panel of B-ALL models representing ETV6 - RUNX1 , BCR - ABL1 , and KMT2A -rearranged subtypes, we show that dual SMARCA2/4 inhibition, using the ATPase inhibitor BRM014 or the PROTAC degrader ACBI1, induces profound loss of viability. This vulnerability is characterized by G0/G1 cell cycle arrest and a robust apoptotic response. Mechanistically, comparative RNA sequencing identified a high-confidence 26-gene “identity core” consistently downregulated upon SWI/SNF disruption with BRM014. This program integrates lymphocyte activation, cytokine signaling, and trafficking modules, including the key niche-interaction receptor CXCR4, and is accompanied by depletion of MYC and E2F transcriptional programs. Finally, BRM014 demonstrated significant growth-inhibitory activity in vivo in an REH xenograft model, with a significant delay in disease progression during the observation window. These findings establish the SWI/SNF complex as a conserved survival dependency in the tested B-ALL models and provide a rationale for targeting SMARCA2/4 to inhibit intrinsic growth in B-ALL.
No takes yet. Share an insight, caveat, or question.
Montenegro-Elvira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: